CONSUN PHARMAC.GR.HD -10 (C1P) - Total Liabilities
Based on the latest financial reports, CONSUN PHARMAC.GR.HD -10 (C1P) has total liabilities worth €1.45 Billion EUR (≈ $1.69 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore C1P operating cash flow to assess how effectively this company generates cash.
CONSUN PHARMAC.GR.HD -10 - Total Liabilities Trend (2021–2024)
This chart illustrates how CONSUN PHARMAC.GR.HD -10's total liabilities have evolved over time, based on quarterly financial data. Check C1P asset resilience ratio to evaluate the company's liquid asset resilience ratio.
CONSUN PHARMAC.GR.HD -10 Competitors by Total Liabilities
The table below lists competitors of CONSUN PHARMAC.GR.HD -10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vir Biotechnology Inc
NASDAQ:VIR
|
USA | $237.55 Million |
|
Ahlatci Dogal Gaz Dagitim Enerji ve Yatirim A.S.
IS:AHGAZ
|
Turkey | TL36.93 Billion |
|
Yinson Holdings Bhd
KLSE:7293
|
Malaysia | RM24.25 Billion |
|
Realia
MC:RLIA
|
Spain | €1.34 Billion |
|
Astrana Health Inc
NASDAQ:ASTH
|
USA | $1.66 Billion |
|
Ellington Financial Inc.
NYSE:EFC
|
USA | $17.48 Billion |
|
China National Electric Apparatus R
SHG:688128
|
China | CN¥-3.44 Billion |
|
ELECTROLUX B ADR/2 SK 5
F:ELXA
|
Germany | €105.92 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down CONSUN PHARMAC.GR.HD -10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CONSUN PHARMAC.GR.HD -10 (C1P) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CONSUN PHARMAC.GR.HD -10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CONSUN PHARMAC.GR.HD -10 (2021–2024)
The table below shows the annual total liabilities of CONSUN PHARMAC.GR.HD -10 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €1.46 Billion ≈ $1.71 Billion |
-8.13% |
| 2023-12-31 | €1.59 Billion ≈ $1.86 Billion |
+9.35% |
| 2022-12-31 | €1.45 Billion ≈ $1.70 Billion |
+0.10% |
| 2021-12-31 | €1.45 Billion ≈ $1.70 Billion |
-- |
About CONSUN PHARMAC.GR.HD -10
Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney… Read more